PAR

6.98%

20.0¢ paradigm biopharmaceuticals limited..

Nicely explained and hence the days 56 and 404 testing points....

First 93 Last

Share
Profile

Follow
Denial

9,850 Posts.

1265

26/07/24

10:09

Post #: 74926981
Share
Originally posted by Torpy: ↑

Mango

I find it really interesting, and a little bit hard to explain, but here goes. The idea of trialling is that you are taking a sample of a large population, and then try to extrapolate how your sample is representative of the whole population - then do that for a placebo and a treatment group to show that if you treat the whole population with the drug or placebo, the drug would give a better outcome on average.

Say you have 2 dartboards, one with pain scores for placebo and one with pain scores for treatment. Your placebo dartboard may go from say 6 to 10. Say your treatment dartboard goes from 5 to 9. How many darts do you need to throw to show that your dartboard has a lower average than the placebo. Maybe quite a few because there is a big overlap of scores

But if your PPS dartboard painscore outcomes are 3 to 7. You could throw far fewer darts and very quickly you will see there is a significant difference in the average of the scores between that and placebo.

So @Mozzarc is right that its about the treatment effect - the greater the differentiation between treatement and placebo, the fewer the samples required to show statistically that one is meaningfully different from the other, and will continue to be that way if you keep throwing millions of darts

Expand

Nicely explained and hence the days 56 and 404 testing points. The max gap to placebo.

In sum:

Any deal that monetises asset will limit potential dilution and bring PARO into play. This is now critical to existing LT holders upside.
Day 404 design also clearly benefits labelling and market proposition for partnering.
PAR Price at posting: 27.0¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BUX

Buxton projects new graphite province discovery at WA Narryer play

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 47 more messages in this thread...

First 93 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 20.0¢		Change -0.015(6.98%)		Mkt cap ! $70.04M

Open	High	Low	Value	Volume
21.0¢	21.0¢	20.0¢	$201.6K	994.6K

Buyers (Bids)

No.	Vol.	Price($)
15	429247	20.0¢

Sellers (Offers)

Price($)	Vol.	No.
21.0¢	13806	2

View Market Depth

No.	Vol.	Price($)
12	389247	0.200
8	133607	0.195
17	238789	0.190
4	92160	0.185
8	122773	0.180

Price($)	Vol.	No.
0.210	13806	2
0.215	28509	1
0.220	59615	6
0.225	28604	2
0.230	16334	2

Last trade - 16.10pm 04/10/2024 (20 minute delay)

PAR (ASX) Chart

Nicely explained and hence the days 56 and 404 testing points....

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Nicely explained and hence the days 56 and 404 testing points....

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News